Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)

NCT04944979 is registered in ClinicalTrials.gov with Kedrion S.p.A. as lead sponsor.

NCT NCT04944979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)
Lead sponsor
Kedrion S.p.A.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 31, 2021
Completion date
May 31, 2027
Enrollment
30 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency disease